Mr. Christopher Barnes reports

SERNOVA TO HOST INVESTOR CALLS TO INTRODUCE NEWLY APPOINTED CEO AND PROVIDE BUSINESS UPDATE

Sernova Corp. will host two investor and analyst conference calls, with corresponding live webcasts.

The first of these two events will introduce the newly appointed chief executive officer, Cynthia Pussinen, as well as the recently appointed chief business officer, Dr. Modestus Obochi, PhD, MBA, and will discuss the overall vision of both executives to deliver novel medical therapies to patients. The second in this series of calls is intended to provide an overall business update and discuss the strategy and operating plans going forward. Details of each event are as follows:

CEO introduction:

Date: Friday, Sept. 15, 2023

Time: 10 a.m. Eastern Time

Dial-in: 1-877-704-4453

Conference ID: 13741199

Business update:

Date: Thursday, Oct. 5, 2023

Time: 10 a.m. Eastern Time

Dial-in: 1-877-704-4453

Conference ID: 13741177

The Oct. 5 event will conclude with a question-and-answer component, and investors can also e-mail questions in advance to info@sernova.com. The company will answer as many questions as allowable within the given time constraints. Subsequently, replays of each event will be available on the events section of the company's website.

About Sernova Corp.

Sernova is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease and blood disorders that include hemophilia A. Sernova is currently focused on developing a functional cure for insulin-dependent diabetes with its lead asset, the Cell Pouch system, a novel implantable and scalable medical device with immune-protected therapeutic cells. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova's Cell Pouch system has demonstrated its potential to be a functional cure for people with Type 1 diabetes in a continuing phase 1/2 clinical study at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the University of Miami to shield therapeutic cells from immune system attack with the goal to eliminate the need for chronic, systemic immunosuppression. In May, 2022, Sernova and Evotec entered into a global strategic partnership to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (Type 1 and Type 2). Sernova continues to progress two additional development programs that utilize its Cell Pouch system: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral factor VIII gene therapy for hemophilia A.

We seek Safe Harbor.